dc.contributor.author | Culhane, Nicole S. | eng |
dc.contributor.author | Graves, Rebecca S. | eng |
dc.date.issued | 2002 | eng |
dc.description.abstract | The thiazolidinediones pioglitazone (Actos) and rosiglitazone (Avandia) are effective at lowering fasting plasma glucose (FPG) and glycosylated hemoglobin (Hb A1c) in patients with type 2 diabetes when used either as monotherapy or in combination with sulfonylureas, metformin, or insulin. The glucose-lowering effects appear comparable with those of sulfonylureas and metformin alone. Currently, there are no randomized trials directly comparing patient-oriented outcomes of the thiazolidinediones with those of sulfonylureas and metformin. Grade of recommendation: B (on the basis of extrapolations from randomized trials and low quality randomized trials). | eng |
dc.identifier.uri | http://hdl.handle.net/10355/2847 | eng |
dc.language | English | eng |
dc.publisher | Family Physicians Inquiries Network | eng |
dc.relation.ispartofcollection | Clinical Inquiries, 2002 (MU) | eng |
dc.relation.ispartofcommunity | University of Missouri--Columbia. School of Medicine. Department of Family and Community Medicine. Family Physicians Inquiries Network | eng |
dc.relation.ispartofseries | Journal of family practice, 51, no. 05 (May 2002): 424. | eng |
dc.rights | OpenAccess. | eng |
dc.rights.license | This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 License. | eng |
dc.subject | pioglitazone | eng |
dc.subject | rosiglitazone | eng |
dc.subject | fasting plasma glucose | eng |
dc.subject | type 2 diabetes | eng |
dc.subject.lcsh | Glycogen -- Metabolism | eng |
dc.subject.lcsh | Rosiglitazone | eng |
dc.subject.lcsh | Diabetes | eng |
dc.subject.mesh | Diabetes Mellitus, Type 2 | eng |
dc.title | How beneficial are thiazolidinediones for diabetes mellitus? | eng |
dc.type | Article | eng |